Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Beer

Showing results (851-860 of 888) with videos related to

Pageof 89
Sort By:
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
Bioorganic & Medicinal Chemistry Letters|October 5, 2010
Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonistsZhicai Yang, David J Fairfax, Jun-Ho Maeng, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2018
LSD1 activates a lethal prostate cancer gene network independently of its demethylase functionArchana Sehrawat, Lina Gao, Yuliang Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
Pageof 89

Showing results (851-860 of 888) with videos related to

Sort By:
Pageof 89
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
Bioorganic & Medicinal Chemistry Letters|October 5, 2010
Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonistsZhicai Yang, David J Fairfax, Jun-Ho Maeng, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2018
LSD1 activates a lethal prostate cancer gene network independently of its demethylase functionArchana Sehrawat, Lina Gao, Yuliang Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
Pageof 89